Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases.

Langer R, Becker K, Feith M, Friess H, Höfler H, Keller G.

Mod Pathol. 2011 Apr;24(4):495-501. doi: 10.1038/modpathol.2010.220. Epub 2010 Dec 3.

2.

Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites.

Sekine S, Nakanishi Y, Ogawa R, Kouda S, Kanai Y.

Virchows Arch. 2009 May;454(5):513-7. doi: 10.1007/s00428-009-0762-6. Epub 2009 Mar 25.

PMID:
19319568
3.
4.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
5.

KIT amplification and gene mutations in acral/mucosal melanoma in Korea.

Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH, Kim KM.

APMIS. 2011 Jun;119(6):330-5. doi: 10.1111/j.1600-0463.2011.02737.x. Epub 2011 Mar 24.

PMID:
21569090
6.

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.

Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, André J, Dumaz N, Ortonne N.

Hum Pathol. 2013 Sep;44(9):1902-11. doi: 10.1016/j.humpath.2013.01.025. Epub 2013 May 9.

7.

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J.

Eur J Cancer. 2012 Jan;48(1):94-100. doi: 10.1016/j.ejca.2011.06.056. Epub 2011 Jul 23.

PMID:
21788131
8.

KIT pathway alterations in mucosal melanomas of the vulva and other sites.

Omholt K, Grafström E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK.

Clin Cancer Res. 2011 Jun 15;17(12):3933-42. doi: 10.1158/1078-0432.CCR-10-2917.

9.

BRAF and c-kit gene copy number in mutation-positive malignant melanoma.

Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ.

Hum Pathol. 2006 May;37(5):520-7.

PMID:
16647948
10.

Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.

Reis RM, Martins A, Ribeiro SA, Basto D, Longatto-Filho A, Schmitt FC, Lopes JM.

Cell Oncol. 2005;27(5-6):319-26.

11.

[ Spectrum of oncogene mutations is different in melanoma subtypes].

Mazurenko NN, Tsyganova IV, Lushnikova AA, Ponkratova DA, Anurova OA, Cheremushkin EA, Mikhailova IN, Demidov LV.

Mol Biol (Mosk). 2015 Nov-Dec;49(6):1022-9. doi: 10.7868/S0026898415060166. Russian.

PMID:
26710785
12.

A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation.

Preto A, Moutinho C, Velho S, Oliveira C, Rebocho AP, Figueiredo J, Soares P, Lopes JM, Seruca R.

Virchows Arch. 2007 Jun;450(6):619-26. Epub 2007 May 9.

PMID:
17487504
13.

Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.

Schirosi L, Lantuejoul S, Cavazza A, Murer B, Yves Brichon P, Migaldi M, Sartori G, Sgambato A, Rossi G.

Am J Surg Pathol. 2008 Nov;32(11):1627-42. doi: 10.1097/PAS.0b013e31817a8a89.

PMID:
18753943
14.

NRAS and BRAF mutation frequency in primary oral mucosal melanoma.

Buery RR, Siar CH, Katase N, Gunduz M, Lefeuvre M, Fujii M, Inoue M, Setsu K, Nagatsuka H.

Oncol Rep. 2011 Oct;26(4):783-7. doi: 10.3892/or.2011.1385. Epub 2011 Jul 11.

PMID:
21750866
15.

KIT mutations in ocular melanoma: frequency and anatomic distribution.

Wallander ML, Layfield LJ, Emerson LL, Mamalis N, Davis D, Tripp SR, Holden JA.

Mod Pathol. 2011 Aug;24(8):1031-5. doi: 10.1038/modpathol.2011.57. Epub 2011 Apr 8.

16.

KIT gene mutations and copy number in melanoma subtypes.

Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL.

Clin Cancer Res. 2008 Nov 1;14(21):6821-8. doi: 10.1158/1078-0432.CCR-08-0575.

17.

V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.

Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP.

J Clin Pathol. 2009 Jul;62(7):613-6. doi: 10.1136/jcp.2009.064550.

PMID:
19561230
18.

Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.

Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS.

Hum Pathol. 2005 Mar;36(3):242-9.

PMID:
15791568
19.

c-kit gene mutation and CD117 expression in human anorectal melanomas.

Ni S, Huang D, Chen X, Huang J, Kong Y, Xu Y, Du X, Sheng W.

Hum Pathol. 2012 Jun;43(6):801-7. doi: 10.1016/j.humpath.2011.08.005. Epub 2011 Dec 9.

PMID:
22154054
20.

Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).

Daniels M, Lurkin I, Pauli R, Erbstösser E, Hildebrandt U, Hellwig K, Zschille U, Lüders P, Krüger G, Knolle J, Stengel B, Prall F, Hertel K, Lobeck H, Popp B, Theissig F, Wünsch P, Zwarthoff E, Agaimy A, Schneider-Stock R.

Cancer Lett. 2011 Dec 15;312(1):43-54. doi: 10.1016/j.canlet.2011.07.029. Epub 2011 Aug 6.

PMID:
21906875
Items per page

Supplemental Content

Write to the Help Desk